As of last Wednesday, Elon Musk's two biggest companies are officially weighing a merger. Would that actually be a good thing for investors?

The combined entity would house rockets, Starlink, Robotaxi, Optimus, Grok, X, and a Mars colony on the to-do list.

Wall Street has a name for that much range: the conglomerate discount.

A widely cited 1995 study put the haircut at 13% to 15%. Investors fear sprawling companies get too costly to run, too opaque to read, and too multifaceted to form a distinct thesis.

Picture a Starlink bull, watching in dismay as Optimus blows through the broader budget.

Of course, nobody sells a vision better than Musk. But getting the market to pay a single multiple for SpaceX (SPCX) and Tesla (TSLA)? That’s a harder sell.

— Brooks & The Street Sheet Team

What: Netflix (NFLX) is the studio Old Hollywood keeps trying to become, and its shares are still down around 25% this year. This week's earnings report showed $17B in content bought just 2% more first-half viewing, plus a cut to ad guidance. If Netflix can’t traverse the modern streaming landscape, who can?

Why: Wall Street sees free cash flow above $12B this year and $21B by decade's end. Netflix's 31% operating margin runs more than 10 points above Walt Disney's (DIS), parks included. In streaming content alone, it vastly outspends Disney's roughly $10B and the $4B Comcast (CMCSA) puts into Peacock. But rivals look worse. Paramount Skydance (PSKY) will spend about $31B on content post-merger, but strip out sports, TV, and theatrical, and streaming gets roughly $9B across several platforms, with $80B in long-term debt behind it.

What Else: The only players that are arguably better positioned sit in Big Tech. Apple (AAPL) spends close to $10B, Amazon (AMZN) over $15B, and YouTube, owned by Alphabet (GOOGL), about $18B in revenue sharing.

Watch: Whether ad revenue steadies after this week's guidance cut. At 18x earnings against 21x for the S&P 500, Netflix now trades below the market. But it might be wise to wait for some good news before hurrying to buy the dip.

What: Tech spent two decades handing chores to consumers, from booking flights to troubleshooting gadgets. Now agents like Muse from Meta (META) and Dots from OpenAI shop, bid, and book on users' behalf. That is, if the merchants let them.

Why: BrightEdge estimates agent purchases are growing 43% month-on-month, up roughly 4x since April. Yet only about 3% of merchants it works with let agents complete a sale. It's often unclear whom an agent represents, mistakes mean returns and chargebacks, and Federal Reserve governor Christopher Waller notes payments now require proving an agent's authority.

What Else: The big retailers are split on how to deal with the rise of AI agents. Amazon (AMZN) bans Muse and Dots from shopping its site, and Rosenblatt Securities argues it has little reason to share a value chain it owns end to end. Target (TGT) admits approved agents only. Walmart (WMT) is courting OpenAI and Google (GOOGL) traffic and reports strong conversion. DoorDash (DASH) is betting on its own agent, Ask.

Watch: Whether Meta puts a rate on the transaction fee Zuckerberg floated in September, and whether Amazon's ban on Muse holds. Merchants spent years paying to be found. Next they may pay to be bought.

What: A year ago, healthcare sat in the bargain bin at a 25% discount to the S&P 500. Last week, as AI jitters got louder, that discount vanished. The new premium may say less about healthcare than investors’ overall market fears.

Why: The Health Care Select Sector SPDR ETF (XLV) now trades at 19.3x forward earnings, a hair above the S&P 500, per FactSet (FDS). Goldman Sachs (GS) says the sector earns a premium when investors trust medical innovation, doubt profits elsewhere, and relax about policy. All three are largely in place.

What Else: In the mid-2000s, energy prices climbed amid Middle East war, the Fed kept hiking, and housing powered profits while the S&P's forward multiple slid from about 18x to 15x. Sound familiar? Past performance doesn’t guarantee future results, but worth noting that in this similar scenario, healthcare kept its premium. Investors who hid there in early 2006 lagged for nearly two years, then fell far less in the crisis, and outperformed for a decade.

Watch: Next month's midterms. If Democrats take either chamber, a divided Congress makes major new legislation unlikely before 2028. For drugmakers, gridlock isn’t a bug, but a feature.